First published: Fri Apr 01 2022(Updated: )
Philips Vue PACS versions 12.2.x.x and prior does not follow certain coding rules for development, which can lead to resultant weaknesses or increase the severity of the associated vulnerabilities.
Credit: ics-cert@hq.dhs.gov
Affected Software | Affected Version | How to fix |
---|---|---|
Philips Myvue | <12.2.1.5 | |
Philips Speech | <12.2.8.0 | |
Philips Vue Motion | <12.2.1.5 | |
Philips Vue PACS | <12.2.8.0 |
Philips has released the following plans to address these vulnerabilities: Philips recommends configuring the Vue PACS environment per D000763414 – Vue_PACS_12_Ports_Protocols_Services_Guide available on Incenter. Philips will release Version 15 in Q1 / 2022 for Speech to remediate this issue and recommends contacting support. Philips will release Version 15 in Q1 / 2022 for MyVue to remediate this issue and recommends contacting support. Philips will release Version 15 in Q1 / 2022 for PACS to remediate this issue and recommends contacting support. Releases are subject to country specific regulations. Users with questions regarding their specific Philips Vue PACS installations and new release eligibility should contact a Philips Sales representative or submit a quote request in the eService portal at: Login - eService (philips.com) The Philips advisory is available. Please see the Philips product security website for the latest security information for Philips products.
Sign up to SecAlerts for real-time vulnerability data matched to your software, aggregated from hundreds of sources.
The severity of CVE-2021-27501 is critical with a score of 9.8.
Philips Vue PACS versions 12.2.x.x and prior are affected by CVE-2021-27501.
The affected software products related to CVE-2021-27501 include Philips Myvue, Philips Speech, Philips Vue Motion, and Philips Vue PACS.
Philips Vue PACS versions 12.2.x.x and prior do not follow certain coding rules for development.
Yes, references for CVE-2021-27501 can be found at the following links: http://www.philips.com/productsecurity and https://www.cisa.gov/uscert/ics/advisories/icsma-21-187-01.